This pie chart shows research & development funding for STI vaccines and diagnostics by topic.
Excerpted from STIs: A Review of the 2022 Vaccine and Diagnostic R&D Pipeline and Investments, the full report is available at stiwatch.org/resource-tracking.
This pie chart shows research & development funding for STI vaccines and diagnostics by sector — public and philanthropic.
Excerpted from STIs: A Review of the 2022 Vaccine and Diagnostic R&D Pipeline and Investments, the full report is available at stiwatch.org/resource-tracking.
This report examines disbursements by the U.S. NIH and the Bill & Melinda Gates Foundation and is one of few reports to track funding trends in vaccine and diagnostics R&D, and pipeline investments for some of the most common STIs, including chlamydia, genital herpes, gonorrhea, hepatitis B, human papillomavirus (HPV), syphilis, and trichomoniasis.
Syphilis rates have increased drastically in recent years. Learn how others are addressing these rising rates and the techniques clinicians are using to detect, treat, and prevent infections.
Co-hosted with NACCHO and NNPTC.
Webinar Recording / Kimberly A Stanford Slides / Anne Rompalo Slides / Irene Stafford Slides
On October 5, The Choice Agenda (TCA) and the National Coalition of STD Directors (NCSD) hosted a discussion on the roll out of Doxycycline as STI PEP for helping gay, bisexual, and other men who have sex with men and transgender women reduce bacterial STIs, including gonorrhea, chlamydia, and syphilis.
Speakers:
Dr. Taimur Khan, Fenway Health
Cait Shea, NCSD
Kendrick Clack, NP, Crofoot MD Clinic/Research Center
Lee Vaughn-Ogin, Bigger Blacker Book
This factsheet provides basic information on sexually transmitted infections (STIs), and a snapshot on the global status of STIs in the context of HIV prevention and global health equity.
Friday, October 7, 2022
Very high STI prevalence is being observed globally. Doxycycline post-exposure prophylaxis (dPEP) has been proposed as an STI prevention strategy to reduce chlamydia, syphilis, and possibly gonorrhea, and trials are ongoing among cisgender gay and bisexual men as well as African cisgender women. Learn about the latest scientific data and more during this Choice Agenda webinar.
Featuring Dr. Connie Celum, Jennifer Mahn, Dr. Victor Omollo, Rodney Perkins and Dr. Jenell Stewart
AVAC’s strategic framework is grounded in a multi-layered approach that carefully considers all of the components needed to achieve the organization’s vision, capitalize on its key strengths, and ensure that AVAC is poised to make an impact on the issues it cares most about over the next five years, and beyond.
The vision describes the world we are striving for. The mission describes what AVAC does in service to achieving this vision. The strategic pillars outline the objectives and approaches that AVAC will take over the next five years to achieve its mission and vision. The strategic pillars are supported by AVAC’s core values—the principles by which we work—as well as a set of key enablers.
In this document, we look at the actions we are taking and those that as a field we all need to take to transform prevention “options” developed through research into prevention “choices” for people that can save lives and help end epidemics. This work is critical, and it is shared – just as we developed our strategic plan and EDI statement in partnership with so many, so too will we move this work forward, together.
As recent-day family planning and reproductive health efforts place greater emphasis on innovation, it is important to remember the value of evidence-based family planning tools that have been effective for decades. Since the physical properties of condoms have not undergone substantial change, many people may forget the power of condoms as a family planning tool. This collection was created as a reminder to all of us that some methods continue to work even as innovations arise.